 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ALG-010133 / Aligos Therap
Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_2246;
No meaningful HBsAg reduction was observed across all cohorts. Further clinical development of ALG-010133 has been discontinued.
- |||| ALG-010133 / Aligos Therap
Trial termination: A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (clinicaltrials.gov) - Mar 15, 2022
P1, N=103, Terminated, Sponsor: Aligos Therapeutics
Further clinical development of ALG-010133 has been discontinued. Active, not recruiting --> Terminated; Lack of antiviral activity at the projected efficacious dose.
- || ALG-010133 / Aligos Therap
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (clinicaltrials.gov) - Mar 2, 2022
P1, N=103, Active, not recruiting, Sponsor: Aligos Therapeutics
Active, not recruiting --> Terminated; Lack of antiviral activity at the projected efficacious dose. Recruiting --> Active, not recruiting | N=164 --> 103 | Trial completion date: Aug 2022 --> Apr 2022 | Trial primary completion date: Aug 2022 --> Apr 2022
- ALG-010133 / Aligos Therap
[VIRTUAL] TRIPLE COMBINATION OF ANTI-HEPATITIS B VIRUS DRUGS DEMONSTRATES SYNERGISTIC ACTIVITY IN VITRO () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1084;
Our HBV siRNA compound, ALG-125903, in combination with our ASO, ALG-020579 and STOPS molecule, ALG-010133, demonstrated synergistic activity in vitro . Further investigation of the strategy to combine HBV siRNA with ASO and STOPS compounds in human clinical trials is warranted .
- ALG-010133 / Aligos Therap
[VIRTUAL] S-ANTIGEN TRANSPORT-INHIBITING OLIGONUCLEOTIDE POLYMERS, (STOPSTM) SEQUESTER CELLULAR PROTEINS TO REDUCE HEPATITIS B VIRUS S-ANTIGEN EXPRESSION AND INCREASE ITS PROTEASOMAL DEGRADATION () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1077;
Our results suggest a mechanism of action for STOPS molecules inhibition of HBV infection and HBsAg production that involves the sequestration of cellular factors needed to express and properly fold the S-antigen . Reduced levels of the cellular factors results in the increased ubiquitination and degradation of HBsAg.
- ALG-010133 / Aligos Therap
[VIRTUAL] IMPROVED LIVER CONCENTRATION AND ACTIVITY OF S-ANTIGEN TRANSPORT-INHIBITING OLIGONUCLEOTIDE POLYMERS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1062;
Furthermore, hepatocyte delivery correlated with antiviral activity in vitro. Improved liver concentrations and activity of GalNAc-conjugated STOPS indicates a potential to significantly reduce the effective antiviral dose for patients.
- ALG-010133 / Aligos Therap
[VIRTUAL] safety, tolerability and pharmacokinetics (pk) of single and multiple doses of alg-010133, an s-antigen transport inhibiting oligonucleotide polymer (stops) for the treatment of chronic hepatitis b (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1138;
ALG-010133 was generally safe and well tolerated in HV as single and multiple SC doses up to 200 and 180 mg, respectively. The PK exposures achieved are expected to result in antiviral activity, supporting the ongoing evaluation in CHB patients.
- ALG-010133 / Aligos Therap
[VIRTUAL] Preclinical Efficacy and Pharmacokinetics of ALG-010133, an S- Antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™) for the Treatment of Chronic Hepatitis B (CHB) () - Feb 9, 2021 - Abstract #APASL2021APASL_82;
- ALG-010133 / Aligos Therap
[VIRTUAL] THE S-ANTIGEN TRANSPORT-INHIBITING OLIGONUCLEOTIDE POLYMER (STOPS™) ALG-010133 DEMONSTRATES A FAVORABLE PRECLINICAL PROFILE FOR THE TREATMENT OF CHRONIC HEPATITIS B () - Oct 11, 2020 - Abstract #AASLD2020AASLD_831;
The PK exposures achieved are expected to result in antiviral activity, supporting the ongoing evaluation in CHB patients. The combination of PK properties enabling SC administration and a favorable safety profile has allowed ALG-010133 to advance into clinical development to be evaluated as a potential treatment for CHB.
- ALG-010133 / Aligos Therap, REP 2139 / Replicor
[VIRTUAL] -ANTIGEN TRAFFIC-INHIBITING OLIGONUCLEOTIDE POLYMERS (STOPS) EFFECTIVELY INHIBIT HEPATITIS B SURFACE ANTIGEN (HBsAg) SECRETION IN BOTH HEPATITIS B VIRUS (HBV) CELL LINES AND HBV INFECTED CELLS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_821;
ALG-010133 demonstrated robust, pan-genotypic inhibition of HBsAg release in multiple cell lines and infected liver cells, with enhanced activity compared to REP-2139. ALG-010133 inhibited HBsAg from the partial HBV genome integrated PLC/PRF 5 cell line, indicating the potential for reducing HBsAg in CHB patients with a high degree of HBV integration.
- ALG-020572 / Aligos Therap
[VIRTUAL] DEVELOPMENT OF A BEST-IN-CLASS HBV ASO, ALG-020572, FOR THE TREATMENT OF CHRONIC HEPATITIS B () - Oct 11, 2020 - Abstract #AASLD2020AASLD_84;
Compared with a single ASO, a 1:1 combination of ALG-020572 and ALG-020576 offers enhanced in vivo potency, better genotypic coverage, a higher resistance barrier and a greater capacity to retain efficacy after HBV genome integration events. This regimen can also be combined with other anti-HBV agents.
- ||| ALG-010133 / Aligos Therap
Enrollment open: A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (clinicaltrials.gov) - Aug 24, 2020
P1, N=164, Recruiting, Sponsor: Aligos Therapeutics
This regimen can also be combined with other anti-HBV agents. Not yet recruiting --> Recruiting
- | ALG-010133 / Aligos Therap
New P1 trial: A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (clinicaltrials.gov) - Jul 23, 2020
P1, N=164, Not yet recruiting, Sponsor: Aligos Therapeutics
- ALG-010133 / Aligos Therap
[VIRTUAL] Combination drug interactions of hepatitis B virus (HBV) S-antigen transport - inhibiting oligonucleotide polymers in vitro (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1834;
STOPs demonstrate an in vitro antiviral profile that suggests they may become an important component of functional cure combination therapy. To this end, our STOP compounds are currently advancing towards combination clinical trials in CHB.